Insider · CIK 0001711393

Shabet Rose Sharon

CIK 0001711393 Name as filed on the most recent filing

Filed as Shabet Rose Sharon (64)

140 transaction lines · from 64 filings · filed 2018-04-05 to 2025-10-09 The span is the filing dates this catalog holds, not the entity's full filing history. Absence here is not evidence of absence at the SEC.

How this page attributes a trade

A line appears here when the filing that carries it names this CIK as a reporting owner, not only when the parser picked this CIK as the line's primary owner. That is why a joint filing appears on both owners' pages rather than vanishing from the second one. The catalog never merges two CIKs into one person and never splits one CIK into two: identity here is the SEC's own identifier and nothing else.

01

Issuers this insider has filed against

Ordered by last-seen filing date, newest first. Roles are as filed on the Form 4 and are not normalised.

Fault

This container could not be filled from the store. It is showing nothing because a read failed, not because no insider filed: those are different facts and this catalog will not let one stand in for the other. The last ingest the store recorded was 2026-08-25 05:24 UTC.

No issuer is recorded

The catalog holds no filing linking this CIK to an issuer.

02

Transactions

Every stored Form 4 line naming this reporting owner, newest transaction date first. Each row links to the filing it came from.

0 transactions · Newest transaction date first, id breaking the tie.

Fault

This container could not be filled from the store. It is showing nothing because a read failed, not because no insider filed: those are different facts and this catalog will not let one stand in for the other. The last ingest the store recorded was 2026-08-25 05:24 UTC.

Transactions filed by this insider
Direction Date Code Company Value USD Filing
2022-09-08 S, Open-market sale Amylyx Pharmaceuticals, Inc.AMLX 1,690,958, disposed Open Form 4 filing 0001140361-22-032970
2022-09-08 S, Open-market sale Amylyx Pharmaceuticals, Inc.AMLX 1,444,331, disposed Open Form 4 filing 0001140361-22-032970
2022-09-08 S, Open-market sale Amylyx Pharmaceuticals, Inc.AMLX 1,039,892, disposed Open Form 4 filing 0001140361-22-032970
2022-09-08 S, Open-market sale Amylyx Pharmaceuticals, Inc.AMLX 489,278, disposed Open Form 4 filing 0001140361-22-032970
2022-09-08 S, Open-market sale Amylyx Pharmaceuticals, Inc.AMLX 231,058, disposed Open Form 4 filing 0001140361-22-032970
2022-03-18 S, Open-market sale Procept BioRobotics CorpPRCT 2 lines 37,345,100, disposed Open Form 4 filing 0000905148-22-000308
2022-01-11 P, Open-market purchase Amylyx Pharmaceuticals, Inc.AMLX 43,700,000, acquired Open Form 4 filing 0001140361-22-001654
2021-09-17 P, Open-market purchase Procept BioRobotics CorpPRCT 14,000,000, acquired Open Form 4 filing 0001567619-21-017393
2021-09-03 S, Open-market sale Figs, Inc.FIGS 1,905,192, disposed Open Form 4 filing 0001567619-21-016763
2021-09-02 S, Open-market sale Figs, Inc.FIGS 7,450,713, disposed Open Form 4 filing 0001567619-21-016763
2021-07-29 P, Open-market purchase Rallybio CorpRLYB 10,478,000, acquired Open Form 4 filing 0001387131-21-007995
2020-12-15 P, Open-market purchase 4D Molecular Therapeutics Inc.FDMT 25,300,000, acquired Open Form 4 filing 0001387131-20-011272
2020-12-14 S, Open-market sale Adaptive Biotechnologies CorpADPT 55,650,000, disposed Open Form 4 filing 0001387131-20-011164
2020-12-01 S, Open-market sale Zentalis Pharmaceuticals, Inc.ZNTL 25,250,000, disposed Open Form 4 filing 0001387131-20-010443
2020-11-11 S, Open-market sale Adaptive Biotechnologies CorpADPT 123,787,500, disposed Open Form 4 filing 0001387131-20-009936
2020-11-11 S, Open-market sale Adaptive Biotechnologies CorpADPT 123,787,500, disposed Open Form 4 filing 0001387131-20-009937
2020-08-26 P, Open-market purchase Inhibrx, Inc.INBX 2 lines 3,409,866, acquired Open Form 4 filing 0001387131-20-008019
2020-08-25 P, Open-market purchase Inhibrx, Inc.INBX 2 lines 1,651,687, acquired Open Form 4 filing 0001387131-20-007889
2020-08-24 P, Open-market purchase Inhibrx, Inc.INBX 897,001, acquired Open Form 4 filing 0001387131-20-007889
2020-04-07 P, Open-market purchase Zentalis Pharmaceuticals, Inc.ZNTL 13,050,000, acquired Open Form 4 filing 0001387131-20-003800
2020-01-28 S, Open-market sale Adaptive Biotechnologies CorpADPT 122,706,039, disposed Open Form 4 filing 0000903423-20-000011
2020-01-28 S, Open-market sale Adaptive Biotechnologies CorpADPT 122,706,039, disposed Open Form 4 filing 0000903423-20-000010
2019-07-01 P, Open-market purchase Adaptive Biotechnologies CorpADPT 5,000,000, acquired Open Form 4 filing 0000903423-19-000273
2019-07-01 P, Open-market purchase Adaptive Biotechnologies CorpADPT 5,000,000, acquired Open Form 4 filing 0000903423-19-000272
2019-06-27 P, Open-market purchase BridgeBio Pharma, Inc.BBIO 80,000,300, acquired Open Form 4 filing 0000903423-19-000265
2019-06-27 P, Open-market purchase BridgeBio Pharma, Inc.BBIO 80,000,300, acquired Open Form 4 filing 0000903423-19-000266
2019-06-19 P, Open-market purchase Urovant Sciences Ltd.UROV 40,495, acquired Open Form 4 filing 0000903423-19-000253
2019-06-19 P, Open-market purchase Urovant Sciences Ltd.UROV 40,495, acquired Open Form 4 filing 0000903423-19-000252
2019-06-18 P, Open-market purchase Urovant Sciences Ltd.UROV 55,061, acquired Open Form 4 filing 0000903423-19-000253
2019-06-18 P, Open-market purchase Urovant Sciences Ltd.UROV 55,061, acquired Open Form 4 filing 0000903423-19-000252
2019-06-17 P, Open-market purchase Urovant Sciences Ltd.UROV 55,825, acquired Open Form 4 filing 0000903423-19-000253
2019-06-17 P, Open-market purchase Urovant Sciences Ltd.UROV 55,825, acquired Open Form 4 filing 0000903423-19-000252
2019-06-14 P, Open-market purchase Urovant Sciences Ltd.UROV 56,514, acquired Open Form 4 filing 0000903423-19-000247
2019-06-14 P, Open-market purchase Urovant Sciences Ltd.UROV 56,514, acquired Open Form 4 filing 0000903423-19-000248
2019-06-13 P, Open-market purchase Urovant Sciences Ltd.UROV 58,543, acquired Open Form 4 filing 0000903423-19-000247
2019-06-13 P, Open-market purchase Urovant Sciences Ltd.UROV 58,543, acquired Open Form 4 filing 0000903423-19-000248
2019-06-12 P, Open-market purchase Urovant Sciences Ltd.UROV 62,244, acquired Open Form 4 filing 0000903423-19-000247
2019-06-12 P, Open-market purchase Urovant Sciences Ltd.UROV 62,244, acquired Open Form 4 filing 0000903423-19-000248
2019-06-11 P, Open-market purchase Urovant Sciences Ltd.UROV 61,694, acquired Open Form 4 filing 0000903423-19-000241
2019-06-11 P, Open-market purchase Urovant Sciences Ltd.UROV 61,694, acquired Open Form 4 filing 0000903423-19-000242
2019-06-10 P, Open-market purchase Urovant Sciences Ltd.UROV 62,594, acquired Open Form 4 filing 0000903423-19-000241
2019-06-10 P, Open-market purchase Urovant Sciences Ltd.UROV 62,594, acquired Open Form 4 filing 0000903423-19-000242
2019-06-07 P, Open-market purchase Urovant Sciences Ltd.UROV 52,959, acquired Open Form 4 filing 0000903423-19-000241
2019-06-07 P, Open-market purchase Urovant Sciences Ltd.UROV 52,959, acquired Open Form 4 filing 0000903423-19-000242
2019-06-06 P, Open-market purchase Urovant Sciences Ltd.UROV 56,621, acquired Open Form 4 filing 0000903423-19-000239
2019-06-06 P, Open-market purchase Urovant Sciences Ltd.UROV 56,621, acquired Open Form 4 filing 0000903423-19-000240
2019-06-05 P, Open-market purchase Urovant Sciences Ltd.UROV 52,418, acquired Open Form 4 filing 0000903423-19-000239

This column is intentionally blank

No transaction line is stored for this reporting owner, though the catalog holds filings naming them. That happens when the filings report only holdings or only positions the store does not carry, and when a parse failed; each filing page states its own parse status.

Codes on this page
S, Open-market sale
Open-market sale
P, Open-market purchase
Open-market purchase

Every value is as reported on the Form 4, totalled to the dollar. Share counts, the price per share and the full list of reporting owners are on each filing's own page, which every row here opens. A row marked n lines adds up that many filed lines of one filing, on one day, on one side of the market; a filing whose lines fall across two pages is left as its lines on both, so no total here is ever short.

What this insider's stored lines contain

No transaction line is stored for this entity, so there is nothing to break down by code. The catalog holds its filings; what it does not hold is a single reportable line from them, which is a fact about the parse and about these filings, not about the entity.

How to cite this page

ebomi catalog. Shabet Rose Sharon, insider transactions. Retrieved 2026-08-25 from https://ebomi.com/insider/0001711393

Balogh, A. Insider trading. Scientific Data 10, 237 (2023) doi:10.1038/s41597-023-02147-6

This page as JSON The JSON twin is shaped by the same read model as this page, so the two cannot disagree. Its envelope carries the canonical URL, the retrieval time, the coverage claim, and the licence statement.